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Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease
relapse and failure of conventional treatments for cancer in childhood or as a first line
treatment for some high-risk cancers. Since hematopoietic stem cells can be found
in the marrow (previously called a bone marrow transplantation) or periphery, we refer
to HSCT as inclusive of HSCT regardless of the origin of the stem cells. HSCT is
associated with adverse side effects, prolonged hospitalization, and isolation. Previous
studies have shown that survivors of HSCT are at particularly high risk for developing
late effects and medical complications, and thus, in addition to survival, quality of life in
survivors of HSCT is an important outcome. This review summarizes and distills findings
on the health-related quality of life (HRQOL) of long-term childhood cancer survivors
of HSCT and examines significant sociodemographic, medical, disease and treatment
correlates of HRQOL, as well as the methodology of the studies (instruments, type
of studies, timing of assessment, type of transplantation). Because previous reviews
covered the studies published before 2006, this review searched three databases
published between January, 2006, and August, 2016. The search identified nine studies,
including 2 prospective cohort studies and 7 cross-sectional studies. All studies reported
a follow-up time of >5 years. The review found that HRQOL is significantly impacted over
time following childhood HSCT, with salient correlates of HRQOL found to be presence
of a severe chronic health or major medical condition, graft vs. host disease (GVHD),
or pain. Continual evaluation of HRQOL must be integrated into long-term follow-up
after childhood HSCT, and intervention should be offered for those survivors with poor
HRQOL. Longitudinal studies should be emphasized in future research to allow for
predictor models of resilience and poor HRQOL.
Keywords: childhood cancer, survivors, hematopoietic stem cell transplant, bone marrow transplant, health-
related quality of life, pain
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INTRODUCTION
New treatments for childhood cancer have resulted in significant
improvements in 5-year survival rates to 80% for most children
(Phillips et al., 2015). It has been estimated that 62% of
adult survivors of childhood malignancy have ≥1 and 38%
≥2 treatment-induced chronic health conditions, and 28% have
a severe or life-threatening problem, especially survivors of
CNS tumors or hematopoietic stem cell transplantation (HSCT)
(Oeffinger et al., 2006; Diller et al., 2009). Advancements in
HSCT have contributed to a dramatic increase in pediatric
cancer survival rates (Clarke et al., 2008). Many children and
adolescents undergo HSCT after disease relapse and failure
of conventional treatments and are vulnerable because HSCT
is typically associated with significant adverse side effects,
prolonged hospitalization, isolation and a high mortality rate 1
year post-transplant (Barrera et al., 2006).
Survivors of HSCT are at risk for late effect complications,
with >90% suffering from at least one and >70% from at least
three chronic conditions (Bhatia et al., 2011). Typical risk factors
related to HSCT include: (1) patients conditioned with total brain
irradiation (TBI), (2) higher-dose conditioning chemotherapy,
(3) treatment before transplant, (4) development of serious
complication after HSCT, (5) potentially toxic supportive care
drugs, and (6) chronic graft vs. host disease (GVHD) (Bhatia
et al., 2011). Various physical symptoms, such as pain, nausea,
and fatigue, further worsen physical dysfunction (Lowe et al.,
2007; Armenian et al., 2011).
In summary, previous studies have highlighted chronic health
conditions found in survivors of childhood HSCT, with those
with GVHD being particularly vulnerable. A study of marrow-
derived HSCT, irrespective of GVHD status (active or resolved),
found a high burden of multiple (≥2) health conditions
(Armenian et al., 2011), that continue to increase with longer-
term follow-up (Sun et al., 2010).
However, health is defined as not merely the absence of
disease but rather a state of complete physical, mental, and social
well-being. Health-related quality of life (HRQOL) is the most
frequently used approach in epidemiological and clinical health
research to assess andmonitor children’s overall QOL (Wallander
and Koot, 2016). HRQOL is a multidimensionality construct
covering physical, emotional, mental, social and behavioral
components of well-being and functioning as perceived by
patients and/or other observers (Ravens-Sieberer et al., 2006).
During the last decade, there have been 4 reviews of the HRQOL
literature on survivors after childhoodHSCT. All concluding that
most survivors have a HRQOL comparable to that of healthy
controls, but there are subgroups that are more vulnerable to
negative impact on HRQOL (Tsimicalis et al., 2005; Clarke et al.,
2008; Packman et al., 2010; Tanzi, 2011). However, the limited
longitudinal studies question the validity of this conclusion
(Tsimicalis et al., 2005; Clarke et al., 2008). In previous studies,
HRQOL was examined before and up to 6 or 12 months post-
HSCT (Clarke et al., 2008; Packman et al., 2010). In addition,
a study by Barrera et al. (2009) assessed HRQOL pre-HSCT
and up to 2 years post-HSCT. These prospective studies suggest
that HRQOL improves over a 4- to 12- and 24-month period
post-transplant. Parsons et al. (2012) emphasized the lack of
studies beyond 5 years post-transplant, even though the majority
of pediatric HSCT recipients are long-term survivors.
We conducted this review to determine how HSCT in
childhood may affect survivors’ HRQOL later in life, with a
specific focus on studies with a long-term focus published in
the last decade. In reviewing studies of HRQOL in long-term
childhood cancer survivors, we also assessed the significant
sociodemographic, health and medical, disease, and treatment
correlates of HRQOL and the methodology of the studies
(instruments, type of studies, timing of assessment, type of
transplantation).
MATERIALS AND METHODS
The online databases Medline (OVID), PubMed, and PsycINFO
were searched using the following terms: hematopoietic stem cell
transplant, bone marrow transplant, child, childhood, children,
adolescent, young adults, survivor, cancer, late effect, health-
related quality of life, quality of life, psychosocial, psychological,
health, pain. This literature search was limited to papers
published between January 2006 and August 2016. The inclusion
criteria were the following: papers in English in a peer-reviewed
journal, at least one formal standardizedHRQOLmeasure, age 21
or younger at transplant, HSCT for malignancy or hematological
disease, HRQOL as an outcomemeasure, and follow-up≥5 years’
post-transplant. We excluded literature reviews, case studies, or
studies involving purely qualitative methodology.
RESULTS
Study Characteristics
We identified 9 studies based on the eligibility criteria. Two were
prospective cohort studies measuring HRQOL up to a mean time
of 13.5 years post-HSCT (Berbis et al., 2013; Schultz et al., 2014).
Seven cross-sectional studies were identified, and four of the nine
were multi-center studies (Michel et al., 2007; Berbis et al., 2013;
Schultz et al., 2014; Kenzik et al., 2015).
All studies, except the study by Kenzik et al. (2015), used
comparisons of outcome with one of the following population
norms: US norms (Forinder et al., 2006), age-matched norms
(Lof et al., 2009), a gender- and age-matched control cohort
(Sanders et al., 2010), other cancer diagnosis/treatment groups
(Michel et al., 2007; Sundberg et al., 2010; Clarke et al., 2011;
Schultz et al., 2014), or both norms and a cancer group (Berbis
et al., 2013). Sample sizes ranged from 18 to 662 (Kenzik et al.,
2015). The mean age at assessments was 8–42 years for cross-
sectional studies and 19.6–20 years for longitudinal, prospective
research. See Table 1.
Regarding transplant type, four studies included patients
undergoing either allogeneic or autologous transplant (Michel
et al., 2007; Sanders et al., 2010; Sundberg et al., 2010; Schultz
et al., 2014; Kenzik et al., 2015), while three studies included
allogeneic patients only (Forinder et al., 2006; Lof et al., 2009;
Clarke et al., 2011; Berbis et al., 2013). Treatment included HSCT
with either marrow- or peripherally-derived stem cells (Forinder
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et al., 2006; Michel et al., 2007; Lof et al., 2009; Sanders et al.,
2010; Sundberg et al., 2010; Clarke et al., 2011; Berbis et al., 2013;
Schultz et al., 2014; Kenzik et al., 2015).
Standardized HRQOL measures were used in all studies,
including 6 different measures (Table 1). The Medical Outcomes
Study 36-Item Short-Form Health Survey (SF-36) (Reulen et al.,
2006) was used in six studies as a measure of HRQOL (Michel
et al., 2007; Sanders et al., 2010; Berbis et al., 2013; Sundberg
et al., 2013; Schultz et al., 2014; Kenzik et al., 2015). One study
used the Pediatric Quality of Life Measure (PedsQL 4.0) (Clarke
et al., 2011). Other QOL measurements included: SEIQoL-DW
(Sundberg et al., 2013), Child Health Questionnaire (SCHQ-
CF87) (Forinder et al., 2006), and The Swedish HRQOL profile
(SWED-QUAL) (Lof et al., 2009). Five studies used survivors’
self-reports (Lof et al., 2009; Sanders et al., 2010; Sundberg et al.,
2013; Schultz et al., 2014; Kenzik et al., 2015), four studies used
both survivors’ self-reports and parent proxy reports (Forinder
et al., 2006; Michel et al., 2007; Clarke et al., 2011; Berbis et al.,
2013), and one study used survivors’ self-reports and teacher
reports (Clarke et al., 2011). Seven studies used generic HRQOL
measures (Michel et al., 2007; Lof et al., 2009; Sanders et al.,
2010; Clarke et al., 2011; Berbis et al., 2013; Schultz et al., 2014;
Kenzik et al., 2015), and two studies used both a generic and a
disease-related measure (Forinder et al., 2006; Sundberg et al.,
2013).
Symptoms of pain in relation to HRQOL were identified in
three studies (Forinder et al., 2006; Lof et al., 2009; Schultz
et al., 2014), and GVHD was assessed in relation to HRQOL in
three studies (Forinder et al., 2006; Lof et al., 2009; Berbis et al.,
2013). A subjective health and symptom inventory checklist,
including a pain scale score and measures of GVHD and late
effects, was used in two studies (Forinder et al., 2006; Lof et al.,
2009). The pain scale included items relating to pain severity,
whereas the subjective symptom scale included items relating to
GVHD and late effects. Schultz et al. (2014) measured cancer-
related pain (from the Childhood Cancer Survivors Study (CCSS)
baseline questionnaire) in addition to using the SF-36. Berbis
et al. (2013) measured GVHD, dividing the HSCT group into two
subgroups with or without post-transplantation chronic graft-
vs.-host disease (cGVHD), and compared health status and QOL
in each of them with the conventional chemotherapy group. In
most studies (Michel et al., 2007; Sanders et al., 2010; Berbis
et al., 2013; Sundberg et al., 2013; Schultz et al., 2014; Kenzik
et al., 2015), pain was measured as part of the SF-36; a separate
standardized pain measure was adopted only in three studies
(Forinder et al., 2006; Lof et al., 2009; Schultz et al., 2014).
The Relationship between Childhood HSCT
and Long-term HRQOL
Contradictory findings were reported in the two longitudinal
studies (Berbis et al., 2013; Schultz et al., 2014). In Berbis
et al. (2013), childhood HSCT adult survivors 12.5 years
post-diagnosis reported lower HRQOL in physical domains,
bodily pain, and general health perceptions compared with the
conventional therapy group. The survivors, as a group, also
reported lower mental composite scores compared to French
norms. However, Schultz et al. (2014) found HRQOL scores to
be similar among treatment groups 13.5 years post-diagnosis. A
cross-sectional study by Michel et al. (2007) found significant
differences in the subscale “General health” and in the Physical
Composite Score 11.9 years post-diagnosis. The HSCT group
reported lower scores than the chemotherapy group, but the
effect sizes were less than 0.2, suggesting uncertain clinical
significance. The cross-sectional study by Sundberg et al. (2013),
with a mean follow-up time of 18 years, also found poorer
overall QOL and more negative outcomes in the HSCT group.
Similarly, the study by Clarke et al. (2011) found HRQOL
scores for the HSCT group to be significantly lower in all
domains compared with both the non-transplanted group and
population norms. In contrast to those studies, the study by
Forinder et al. (2006) showed that HRQOL 8 years post-diagnosis
was overall comparable with norms, although bodily pain was
higher and general self-esteem lower, and parents reported lower
psychosocial and physical HRQOL for their children. However,
Lof et al. (2009) found 17 years post-diagnosis that physical
HRQOL was reported to be poorer post-HSCT compared with
age-matched norms. Similarly, Sanders et al. (2010) found
physical functioning to be worse in the transplanted patients 16.2
years post-diagnosis compared with a gender-and age-matched
control cohort.
Variables Associated with HRQOL in
Long-term Survivors of Childhood HSCT
Variables associated with poor HRQOL in long-term adult
survivors of childhood HSCT based on multivariate analyses,
included unemployment or being on sick leave (Sundberg et al.,
2013), female gender (Sanders et al., 2010), >18 years after
transplant (Sanders et al., 2010), physical symptoms (Kenzik
et al., 2015), a severe chronic health condition or major medical
condition (Michel et al., 2007; Schultz et al., 2014), myeloid
malignancy diagnosis (Sanders et al., 2010), cancer-related pain
(Schultz et al., 2014), and GVHD (Forinder et al., 2006; Berbis
et al., 2013). Sanders et al. (2010) found more time elapsed
post-HSCT to be associated with poorer HRQOL.
DISCUSSION
This review investigated HRQOL in long-term survivors of
childhood HSCT. Most studies identified compromised HRQOL
compared with conventional therapy groups and population
norms (Forinder et al., 2006; Michel et al., 2007; Lof et al.,
2009; Sanders et al., 2010; Clarke et al., 2011; Berbis et al.,
2013; Sundberg et al., 2013). This finding is in contrast to a
previous review by Clarke et al. (2008), who noted improvement
in HRQOL 12–24 months post-transplant. This discrepancy
suggests that a to-be-determined minimum amount of years are
necessary to detect late effects on HRQOL. The studies included
in the present review had a minimum follow-up time since
diagnosis of 5 years; however, themean follow-up time for several
studies was greater than 18 years.
Factors associated with long-term HRQOL include
unemployment or being on sick leave, time since HSCT,
Frontiers in Psychology | www.frontiersin.org 6 March 2017 | Volume 8 | Article 253
Reinfjell et al. HRQOL in Long-term Survivors of HSCT in Childhood
physical symptoms, a severe chronic health condition/major
medical condition, cancer-related pain, and GVHD. Previous
studies have reported contradictory results regarding correlates
of HRQOL and psychological symptom outcomes. Childhood
HSCT survivors overall were found to havemoremedical adverse
effects or HSCT-related complications (Lee et al., 2006), that was
strongly associated with worse HRQOL. Two studies found an
early reduction in HRQOL immediately after allogeneic HSCT
but a consistent recovery to baseline levels thereafter (Notteghem
et al., 2003; Barrera et al., 2009). However, Clarke et al. (2008)
emphasized that, although HRQOL is within the baseline range
1 year post-transplant, accumulating evidence suggests that the
pre-transplant baseline is seriously compromised by the disease
for which the patient is being transplanted. In this regard, the
severity of the disease prior to transplantation (e.g., myeloid
malignancy) may infer a higher likelihood of poor HRQOL after
transplantation (Sanders et al., 2010).
Baker and Fraser (2008) indicate that the strongest association
between reduced HRQOL and impaired functional status
following HSCT is the presence of chronic GVHD, which can
negatively impact physical and mental health and lead to the
development of functional impairment and activity limitations
over a lifetime (Lee et al., 2006). Research on pediatric HSCT
focusing on GVHD is limited. Very long-term follow-up is
important and large-scale studies are lacking (Bhatia et al.,
2011; Parsons et al., 2012). In the present review, only the
longitudinal study by Berbis et al. (2013) found that childhood
HSCT survivors with GVHD had a higher association with late
effects and reported greater reduction in HRQOL than survivors
without GVHD. In that study, 74.6% of 256 HSCT survivors had
allogeneic HSCT.
Only three studies have had a specific focus on pain and
its relationship with HRQOL. In a previous study, allogeneic
HSCT recipients with active chronic GVHD had the strongest
association between poorer HRQOL and poor general health,
functional impairment, and pain (because of cancer or its
treatment) compared with CCSS survivors without GVHD
(Armenian et al., 2011). However, most of the studies in the
present review only measured pain using the two pain items in
the SF-36. Only one study by Schultz et al. (2014) also included
self-reported cancer-related pain (CCSS–baseline study), and
the studies by Forinder et al. (2006) and Lof et al. (2009)
included a pain scale measured by the Subjective Health and
Symptom Inventory checklist. In the present review, Forinder
et al. (2006) reported an association between HRQOL among
childhood HSCT survivors and bodily pain, general health, and
self-esteem. Schultz et al. (2014) found that, among allogeneic
HSCT survivors (28% with a history of GVHD), the presence
of a severe chronic health condition was associated with a
lower physical mean summary score; however, these survivors
were no more likely to report cancer-related pain or cancer-
related anxiety than comparison cohorts. Overall HRQOL scores
were similar among the treatment groups, although survivors
reporting more health conditions or cancer-related pain were
more likely to have diminished HRQOL. These results are similar
to those in the Sanders et al. (2010) study. However, these findings
suggest that complications and diminished physical functioning
may be problematic outcomes of acute myeloid leukemia (AML)
vs. acute lymphoblastic leukemia (ALL) survivors of HSCT.
Mulrooney et al. (2008), reporting from the CCSS, emphasized
that both chronic fatigue and pain as long-term outcomes should
be further investigated.
There is a need for longer-term longitudinal studies in
childhood HSCT survivors as late effects may not be visible until
later in life. Unfortunately, only two longitudinal studies with
a mean follow-up time of 12.5 (Berbis et al., 2013) and 13.5
years (Schultz et al., 2014) were found. The other seven were
cross-sectional.
The low number of research studies found for this review
limits strong conclusions, as cross-sectional data in the majority
prevent the estimation of causal relationships among variables.
Statistical power is usually not stated or insufficient to detect
significance, effect-sizes are often not reported when results are
significant, and the four single-center studies lack generalizability
to other treatment sites. Further, more ethnically diverse samples
would lend greater generalizability to the findings. Recruitment
bias needs to be considered any long-term outcome studies
since survivors with diminished HRQOL may be less likely
to participate. The single study by Schultz et al. (2014)
examining recruitment bias found no demographic or medical
differences between participants and non-participants treated
on identical protocols. Children with cancer received HSCT
for different types of cancer and with varied levels of disease,
thus the heterogeneity of the samples further reduce likelihood
of consistent findings across studies. Long-term HRQOL also
should be compared between childhood cancer survivors who
received allogeneic vs. autologous HSCT. Encouragingly, five
of the studies in this present review were multicenter studies,
and six of the studies used the same HRQOL measurement
(SF-36), enabling comparisons between the studies. Larger
longitudinal studies are needed to confirm these findings in
medically and demographically diverse samples. We emphasize
the need for prospective longer-term studies of late effects
and HRQOL following childhood HSCT. Risk factors related
to the development of chronic pain require more study.
Interventions to prevent chronic health conditions and reduce
cancer-related pain must be developed. Studies are needed
in the prevention of poor HRQOL during treatment, as
well as interventions for those survivors with compromised
HRQOL.
CONCLUSION
While many survivors of childhood HSCT enjoy good HRQOL,
those with a severe chronic health condition or a major medical
condition, GVHD, or pain appear to have the greatest association
with poor HRQOL. Survivors of childhood HSCT require on-
going, life-long monitoring as many late adverse effects may not
become manifest for years or even decades after transplantation.
HRQOL issues should be discussed with patients, and survivors
should be informed about possible late effects to enhance
monitoring and prevention. Interventions addressing HRQOL in
this survivor population should become a priority. Long-term
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longitudinal studies should be emphasized in future research in
childhood HSCT survivors, including a specific focus on pain.
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